SK Biopharmaceuticals has signed a licensing agreement with another South Korean drug developer to add a preclinical Parkinson’s disease therapy to its pipeline. The deal is structured as a biobucks pact, with a total potential value of $314.8 million if all milestones are met.
The candidate is the second preclinical Parkinson’s treatment in SK’s portfolio, signaling a deeper push into early-stage neuroscience research. The agreement follows a typical biobucks structure, where the upfront payment is supplemented by future development and commercial milestones.
This move underscores SK’s continued focus on central nervous system disorders, particularly Parkinson’s disease. By licensing an external asset rather than relying solely on internal discovery, the company is broadening its early-stage options in a competitive therapeutic area.